Targeted Nanomedicines for Cancer Therapy, From Basics to Clinical Trials
Traditional systemic chemotherapy involves the wide distribution of drug molecules in the body, causing toxic side effects in the healthy tissues and limiting the therapeutic dose required at the site of drug action. In order to decrease side effects and increase the drug efficacy, recent research...
Main Authors: | Zahra Eskandari, Fatemeh Bahadori, Burak Celik, Hayat Onyuksel |
---|---|
Format: | Article |
Language: | English |
Published: |
Canadian Society for Pharmaceutical Sciences
2020-05-01
|
Series: | Journal of Pharmacy & Pharmaceutical Sciences |
Online Access: | https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/30583 |
Similar Items
-
Targeted Sterically Stabilized Phospholipid siRNA Nanomedicine for Hepatic and Renal Fibrosis
by: Fatima Khaja, et al.
Published: (2016-01-01) -
Nanomedicine in Action: An Overview of Cancer Nanomedicine on the Market and in Clinical Trials
by: Ruibing Wang, et al.
Published: (2013-01-01) -
Endocytosis and Organelle Targeting of Nanomedicines in Cancer Therapy
by: Wang X, et al.
Published: (2020-11-01) -
Mitochondria-Targeted Nanomedicine for Enhanced Efficacy of Cancer Therapy
by: Yan Gao, et al.
Published: (2021-08-01) -
Hyaluronic Acid-Coated Nanomedicine for Targeted Cancer Therapy
by: Kibeom Kim, et al.
Published: (2019-06-01)